Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S100B | P04271 | 1/20 | 0.70 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.61 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.60 |
| ▸ | CA12 | O43570 | 2/20 | 0.60 |
| ▸ | CA2 | P00918 | 2/20 | 0.60 |
| ▸ | CA9 | Q16790 | 2/20 | 0.60 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | NQO2 | P16083 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5437012 | 1.00 | S100B (0.70) | S100BNFE2L2PTGS2PTGS1CA12 | |
| SCHEMBL2904629 | 1.00 | S100B (0.70) | S100BNFE2L2PTGS2PTGS1CA12 | |
| SCHEMBL2904627 | 1.00 | S100B (0.70) | S100BNFE2L2PTGS2PTGS1CA12 | |
| SCHEMBL10412841 | 0.91 | S100B (0.82) | S100BPTGS2PTGS1CA12CA2 | |
| SCHEMBL2010515 | 0.91 | S100B (0.82) | S100BPTGS2PTGS1CA12CA2 | |
| SCHEMBL10733285 | 0.91 | S100B (0.82) | S100BPTGS2PTGS1CA12CA2 | |
| SCHEMBL12416630 | 0.91 | S100B (0.82) | S100BPTGS2PTGS1CA12CA2 | |
| SCHEMBL10733277 | 0.91 | S100B (0.82) | S100BPTGS2PTGS1CA12CA2 | |
| SCHEMBL4787112 | 0.88 | S100B (0.56) | S100BNFE2L2PTGS2PTGS1CA12 | |
| SCHEMBL4787108 | 0.88 | S100B (0.56) | S100BNFE2L2PTGS2PTGS1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3707132-B1 | NEW METHOD FOR THE SYNTHESIS OF UNSYMMETRICAL TERTIARY AMINES | UNIV PARIS SACLAY (FR) | 2024-07-17 | — | — | EP | disclosed |
| US-11034646-B2 | Method for the synthesis of unsymmetrical tertiary amines | Universite Paris-Saclay (FR) | 2021-06-15 | — | — | US | disclosed |
| US-20200255369-A1 | NEW METHOD FOR THE SYNTHESIS OF UNSYMMETRICAL TERTIARY AMINES | Universite Paris-Saclay (FR) | 2020-08-13 | — | — | US | disclosed |
| WO-2019063952-A1 | NEW METHOD FOR THE SYNTHESIS OF UNSYMMETRICAL TERTIARY AMINES | UNIVERSITE PARIS-SUD (FR) | 2019-04-04 | — | — | WO | disclosed |
| US-9745288-B2 | Compounds and methods for treating cancer by inhibiting the urokinase receptor | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| US-9745288-B2 | Compounds and methods for treating cancer by inhibiting the urokinase receptor | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| US-20150051247-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER BY INHIBITING THE UROKINASE RECEPTOR | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2015-02-19 | — | — | US | disclosed |
| US-20150051247-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER BY INHIBITING THE UROKINASE RECEPTOR | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2015-02-19 | — | — | US | disclosed |
| WO-2013025939-A2 | COMPOUNDS AND METHODS FOR TREATING CANCER BY INHIBITING THE UROKINASE RECEPTOR | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2013-02-21 | — | — | WO | disclosed |
| US-20110172234-A1 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110172234-A1 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-07-14 | — | — | US | disclosed |
| US-7915245-B2 | Using small molecules as binding ligands, for the recruitment of Fas-associated death domain protein, activation of death-inducing signaling complex, caspase-8, and apoptosis in malignant cells; anticarcinogens, antitumor agents; enhanced cellular differentiation, minimizing cytolysis to healthy cells | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915245-B2 | Using small molecules as binding ligands, for the recruitment of Fas-associated death domain protein, activation of death-inducing signaling complex, caspase-8, and apoptosis in malignant cells; anticarcinogens, antitumor agents; enhanced cellular differentiation, minimizing cytolysis to healthy cells | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-03-29 | — | — | US | disclosed |
| US-20080214547-A1 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | UNIVERSITY OF MARYLAND, BALTIMORE | 2008-09-04 | — | — | US | disclosed |
| US-20080214547-A1 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | UNIVERSITY OF MARYLAND, BALTIMORE | 2008-09-04 | — | — | US | disclosed |
| WO-2008094319-A2 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYTEM (US) | 2008-08-07 | — | — | WO | disclosed |
| US-20070122341-A1 | Benzylideneaniline derivatives and their radioisotope labeled compounds for binding and imaging of beta-amyloid plaques | SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255369-A1 | NEW METHOD FOR THE SYNTHESIS OF UNSYMMETRICAL TERTIARY AMINES | ADH1C, ADH1A, ADH5 | S100B 3594/4885NFE2L2 3213/4885PTGS2 3275/4885 |
| US-20150051247-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER BY INHIBITING THE UROKINASE RECEPTOR | PLAUR, PLAU, PLG | S100B 2194/4885NFE2L2 2521/4885PTGS2 387/4885 |
| US-20080214547-A1 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | BID, BAD, MCL1 | S100B 4126/4885NFE2L2 2158/4885PTGS2 1147/4885 |
| US-11034646-B2 | Method for the synthesis of unsymmetrical tertiary amines | ADH1C, PNMT, ADH1A | S100B 3361/4885NFE2L2 3096/4885PTGS2 3092/4885 |
| US-20110172234-A1 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | BID, BAD, MCL1 | S100B 4126/4885NFE2L2 2158/4885PTGS2 1147/4885 |
| US-20070122341-A1 | Benzylideneaniline derivatives and their radioisotope labeled compounds for binding and imaging of beta-amyloid plaques | APP, BACE1, APBA1 | S100B 219/4885NFE2L2 546/4885PTGS2 3666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.